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Abstract
The glycopeptides (particularly vancomycin) have been the recommended therapy for
serious  methicillin‐resistant  Staphylococcus  aureus  (MRSA) infections.  The increased
incidence of MRSA has led to the frequent use of vancomycin. Unfortunately, with the
increased use of vancomycin, isolates of S. aureus have been discovered with reduced
susceptibility  to  vancomycin.  Several  studies  suggest  that  reduced  vancomycin
susceptibility  is  associated  with  vancomycin  treatment  failure.  Various  forms  of
glycopeptide resistance have appeared in MRSA strains, including high‐level resistance,
homogeneous and heterogeneous intermediate resistance. While vancomycin‐resistant
S. aureus (VRSA) strains are limited to a handful of reported cases and vancomycin‐
intermediate S. aureus (VISA) strains remain rare; heterogeneous VISA (hVISA) strains
are more common. This article summarizes the current knowledge regarding the history,
definition, mechanisms, detection methods, epidemiology and clinical significance of
‘glycopeptide resistance in S. aureus’ and discusses therapeutic optıons for the treatment
of hVISA/VISA infections.
Keywords: S. aureus, glycopeptide resistance, vancomycin, teicoplanin, hVISA, VISA
1. Introduction
Glycopeptide group antibiotics—notably vancomycin—have traditionally been the mainstay
of therapy for infections caused by methicillin‐resistant Staphylococcus aureus  (MRSA) [1].
However, the increased incidence of MRSA infections has led to increased use of vancomycin
and has resulted in the emergence of S. aureus with reduced susceptibility to vancomycin. Both
the terms vancomycin‐intermediate S. aureus (VISA) and glycopeptide‐intermediate S. aureus
(GISA) have been used in the literature [2]. Since many VISA isolates also have been inter‐
mediate to glycopeptide teicoplanin, the term GISA may be more accurate. However, the
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acronym VISA is more frequently used. Various studies have associated the presence of VISA
and heterogeneous VISA (hVISA) with vancomycin treatment failure.
This article focuses on the history, definition, mechanisms, detection methods, epidemiology,
and clinical significance of ‘glycopeptide resistance in S. aureus’ and the therapeutic options
for the treatment of hVISA/VISA infections.
2. History and definition of glycopeptide resistance
The glycopeptide vancomycin was isolated from a Gram‐positive filamentous actinomycete
called Amycolatopsis orientalis and was approved for use by the U.S. Food and Drug Adminis‐
tration in 1958 [2, 3]. Vancomycin acts by inhibiting proper cell wall synthesis. It binds with
high affinity to D‐alanyl‐D‐alanine (D‐Ala‐D‐Ala) terminal end of peptidoglycan precursors
and prevents cross‐linking of peptidoglycan by inhibiting the action of transglycosidase and
transpeptidases. Vancomycin has been in clinical use for decades and there was no notable
resistance to vancomycin reported in S. aureus until 1996. In 1996, a MRSA strain with vanco‐
mycin MIC of 8 μg/ml (Mu50, VISA) was isolated from the surgical wound infection from a 4‐
month‐old male infant who had undergone cardiac surgery [4]. After this case, two patients
from USA and one patient from France with infections due to S. aureus with intermediate
resistance to vancomycin were reported [5, 6]. After the emergence of VISA; a new model of
vancomycin resistance (hVISA) was defined by Hiramatsu et al. in 1997 [7]. The first hVISA
strain Mu3 was isolated from the sputum of a 64‐year‐old patient with MRSA pneumonia who
failed vancomycin therapy. hVISA strains are susceptible to vancomycin by the standard broth
microdilution reference method (vancomycin MIC ≤2 μg/ml) but contain subpopulations of
cells (one in every 105–106) for which the vancomycin MIC is in the intermediate range,
currently defined as 4–8 μg/ml by the Clinical and Laboratory Standards Institute (CLSI) [8].
hVISA strains are more commonly found than VISA and different rates of hVISA are reported
from different countries.
In 2002, the first S. aureus fully resistant to vancomycin [vancomycin‐resistant S. aureus (VRSA),
vancomycin MIC ≥16 μg/ml] was reported in Michigan, United States (U.S). Fortunately, VRSA
is very rare as only 14 cases of VRSA have been reported in U.S. so far [9].
3. Phenotypic changes and mechanisms of resistance
3.1. hVISA and VISA
Heterogeneous VISA appears to be the phase before the development of VISA. Vancomycin
exhibits a selective pressure that leads to the growth of VISA subpopulations, eventually
creating a uniform population of VISA [10].
One of the most common phenotypic changes observed in hVISA/VISA is the thickened cell
wall with reduced peptidoglycan cross‐linking (Figure 1) [2, 10, 11]. Reduced cross‐linking of
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peptidoglycan leads to an increase in free D‐Ala‐D‐Ala residues (binding sites for vancomy‐
cin). It is supposed that vancomycin binds to these free D‐Ala‐D‐Ala residues in the outer layers
of the thickened cell wall and is unable to reach its site of action at the cell membrane [12]. The
trapped vancomycin molecules within the cell wall clog the peptidoglycan meshwork and
form a physical barrier towards further incoming vancomycin molecules. Thus, collaboration
of the clogging and cell wall thickening leads to glycopeptide resistance (Figure 2) [13, 14].
Figure 1. Comparison of the cell wall thickness of S. aureus ATCC 29213 [Vancomycin‐susceptible S. aureus (VSSA)],
hVISA and VISA strains by transmission electron microscopy. The cell wall thickness, in nanometers (mean ± SD), is
given under each image. Magnification: × 60,000. (Adapted from Ref. [11] which was published under an open‐access
license agreement).
Figure 2. Model depicting the resistance mechanisms of hVISA/VISA. CW, cell wall; CM, cell membrane; PG, peptido‐
glycan. (Adapted with permission from Ref. [14]).
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In addition to thickened cell wall, hVISA/VISA strains exhibit other phenotypic changes
including reduced autolytic activity, reduced hemolytic activity and slow growth in vitro
[10, 15].
3.1.1. Molecular mechanisms of resistance
The molecular mechanisms of glycopeptide resistance in hVISA/VISA are still not clearly
understood. To date, no specific genetic determinants of hVISA/VISA have been defined.
However, some of the genes whose expression has been found to be altered in VISA strains
include atl (autolysin), mprF (phosphatidylglycerol lysyltransferase), sceD (transglycosylase),
sarA, sigB, tcaA, and ddh [16]. Furthermore, mutations associated with the intermediate
resistance phenotype have been identified in the two‐component regulatory systems [vraSR
(vancomycin resistance‐associated sensor/regulator), graSR (glycopeptide resistance‐associat‐
ed sensor/regulator), walKR], and rpoB (RNA polymerase) gene [15].
Cellular physiology of hVISA/VISA is believed to be altered due to the cumulative effects of
mutations and/or modulation of regulatory systems [17]. As a result, altered cell wall structure
and metabolism resulting from multiple genetic changes appears to be responsible for
intermediate resistance to glycopeptides.
3.2. VRSA
The mechanism of vancomycin resistance in VRSA strains is different from that of hVISA/VISA
strains. The vanA gene complex, which confers high‐level resistance to glycopeptides in
enterococci, was detected in VRSA isolates.
To date, nine types of glycopeptide resistance have been described in enterococci. Eight of these
types (VanA, VanB, VanD, VanE, VanG, VanL, VanM, and VanN) correspond to acquired
resistance, whereas VanC is an intrinsic characteristic of Enterococcus gallinarum and Entero‐
coccus casseliflavus. Glycopeptide resistance in enterococci results from the production of
modified peptidoglycan precursors ending in D‐alanyl‐D‐lactate (D‐Ala‐D‐Lac) (VanA, VanB,
VanD, and VanM) or D‐alanyl‐D‐serine (D‐Ala‐D‐Ser) (VanC, VanE, VanG, VanL, and VanN)
to which vancomycin binds with low affinity and the elimination of high‐affinity precursors
ending in D‐Ala‐D‐Ala [18].
Resistance in VRSA isolates is caused by the horizontal transfer of transposon Tn1546 (carry‐
ing the vanA operon) from vancomycin‐resistant Enterococcus faecalis [15, 19]. Vancomycin is
known to act by binding to the terminal D‐Ala‐D‐Ala of bacterial cell wall precursors. The
vanA gene complex acquired by VRSA strains enables the bacteria to synthesize cell wall pre‐
cursors terminating in D‐Ala‐D‐Lac for which vancomycin has a greatly decreased affinity.
In the presence of vancomycin, the novel cell wall precursors are synthesized, allowing con‐
tinued peptidoglycan assembly [19, 20].
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4. Laboratory detection of hVISA, VISA and VRSA
Laboratory detection of VISA and VRSA strains is easier than hVISA, as there are defined CLSI
MIC criteria (MIC: 4–8 μg/ml for VISA and MIC ≥16 μg/ml for VRSA). These criteria have been
defined using the reference broth microdilution (BMD) method. Results obtained by the use
of other methods for determining the MIC should be confirmed with BMD [21]. Disk diffusion
(Kirby‐Bauer) is not an acceptable method for vancomycin susceptibility testing of S.aureus
isolates.
Detection of hVISA is problematic for most clinical microbiology laboratories. The lack of a
precise definition and standardized testing makes the detection of hVISA difficult [21]. hVISA
strains appear susceptible to vancomycin (MIC ≤ 2 μg/ml) with conventional testing but
contain subpopulations (1 per 105–106 organisms) that express reduced vancomycin suscepti‐
bility (MIC ≥4 μg/ml). Standardized methods for susceptibility testing [broth microdilution
(BMD), agar dilution and standard Etest]—which use an inoculum of only 5 × 104 colony‐
forming unit (CFU)/well (BMD) or 1 × 104 CFU/spot (agar dilution)—fail to detect hVISA, in
part due to the small inoculum, the relatively poor support of growth on Mueller‐Hinton agar
(MHA) plates, or a combination of both [2, 22].
The morphological features of hVISA/VISA isolates can be different from those of standard S.
aureus cultures on agar plates. Careful observation may reveal smaller‐sized colonies,
“mixed” colony morphology (large and small colonies or colonies with different pigmenta‐
tions in a pure culture) and reduced pigmentation. However, these changes may be subjective
and are not diagnostic [2, 21].
Methods for “hVISA detection” use higher inoculum, prolonged incubation or more nutritious
agar to promote the growth of subpopulations with reduced susceptibility to vancomycin.
Population analysis profile‐area under the curve (PAP‐AUC) is considered the gold standard
method for hVISA detection. However, this method is labor‐intensive, time‐consuming and
not suitable for routine use in clinical microbiology laboratories [10, 22]. As a consequence,
several screening methods have been developed for the detection of hVISA.
4.1. Screening methods for hVISA
4.1.1. Screening plates
A number of screening plates containing various concentrations of vancomycin or teicopla‐
nin have been proposed for the detection of hVISA/VISA isolates [brain heart infusion agar
(BHIA) with 3 μg/ml, 4 μg/ml or 6 μg/ml vancomycin, BHIA with 5 μg/ml teicoplanin, MHA
with 5 μg/ml vancomycin or 5 μg/ml teicoplanin] [23–26]. Figure 3 shows the growth of a
hVISA strain on BHIA with 4 μg/ml vancomycin.
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Figure 3. Photograph of a hVISA grown on BHIA with 4 μg/ml vancomycin for 24 and 48 h.
Antibiogram Committee of the French Society for Microbiology recommends the use of MHA
with 5 μg/ml teicoplanin (MHA5T). This screening plate has been tested by various studies
using an inoculum of 10 μl of a 2.0 McFarland standard suspension for the detection of VISA/
hVISA isolates. Growth of one or more colonies is considered positive after 48 h of incubation.
MHA5T has been shown to have sensitivity ranging from 65% to 79% and specificity ranging
from 35 to 95% for the detection of hVISA [2].
In a study conducted by Satola et al., BHIA containing 4 μg/ml vancomycin and 16 g/l
pancreatic digest of casein has been shown to be 90% sensitive and 95% specific with a 0.5
McFarland inoculum and 100% sensitive and 68% specific with a 2.0 McFarland inoculum
[22]. However, further studies are needed to determine the value of this screening plate.
4.1.2. Etest macromethod
Etest macromethod is performed utilizing a higher inoculum of organism (2.0 McFarland vs.
0.5 McFarland utilized in standard Etest) streaked onto BHIA. Vancomycin and teicoplanin
Etest strips are applied to the dry agar surface and read after 48 h of incubation (compared to
24 h for standard Etest) at 35°C [10]. Zones must be read at complete inhibition, with care, to
visualize hazy growth or microcolonies. Heteroresistance is defined as MICs for vancomycin
and teicoplanin of ≥8 μg/ml or a teicoplanin MIC of ≥12 μg/ml alone. It should be noted that
the result of the Etest macromethod is just a cutoff level and is not a true MIC, because this
method differs from the standard MIC calculation [2, 21].
Figure 4 shows a hVISA strain (confirmed by PAP‐AUC) with positive Etest macromethod
result. The presence of microcolonies inside the inhibition zones reflects the heterogeneous
resistant character of the strain (Figure 5). Subculture from a single microcolony (Figure 5B)
done on blood agar reveals heterogeneous colony morphology (a common feature of hVISA/
VISA strains) (Figure 6).
Various studies have evaluated the performance of Etest macromethod, using PAP‐AUC as
the gold standard. Etest macromethod has been shown to have sensitivity ranging from 57 to
98.5% and specificity ranging from 55 to 96% for the detection of hVISA [22, 23, 25, 27–29]. The
differences in sensitivity and specificity rates may be partially explained by the use of various
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inoculum sizes for Etest macromethod (50, 100 or 200 μl) in different studies [27, 28, 30].
Currently, the manufacturer recommends the use of an inoculum of 100 μl [31].
Figure 4. Positive Etest macromethod result for a hVISA strain isolated from blood culture A: Vancomycin Etest, B:
Teicoplanin Etest.
Figure 5. Magnified appearance of Figure 4(A and B). The arrows indicate the presence of microcolonies growing
within the zones of inhibition. A: Vancomycin Etest, B: Teicoplanin Etest.
Figure 6. Subculture from a single microcolony (Figure 5B) on blood agar demonstrating different colony morpho‐
types.
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4.1.3. Etest GRD
Etest glycopeptide resistance detection (GRD) is a newer Etest method for the detection of
hVISA. This method involves the use of a double‐ended Etest strip that contains vancomycin,
teicoplanin, and a nutritional supplement to enhance the growth of hVISA. A 0.5 McFarland
standard inoculum, rather than the 2 McFarland standard used for Etest macromethod, is used
and inoculated onto MHA + 5% blood [2]. Etest GRD strip is applied to the agar surface and
the zone of inhibition is read after 48 h of incubation at 35°C. The strain is considered positive
for hVISA if the Etest GRD result is ≥8 μg/ml for either vancomycin or teicoplanin [21, 22].
Figure 7 shows a hVISA strain with positive Etest GRD result.
Figure 7. A hVISA strain with positive Etest GRD result. (Photograph courtesy of Dr M. Wootton).
Etest GRD has been reported to have sensitivity and specificity of 57–94% and 82–97%,
respectively [22, 28, 29, 32]. Some of these differences may reflect the instability of hVISA
phenotype. hVISA strains are known to be unstable, with the ability to revert to vancomy‐
cin‐susceptible S. aureus (VSSA) under various conditions, including passage of the isolate on
vancomycin‐free media [29].
A possible barrier to large‐scale usage of modified Etest methods is the potentially high cost
to the clinical laboratory. This can be considered a disadvantage [10].
4.2. Confirmatory methods for hVISA
4.2.1. PAP‐AUC
Population analysis profile‐area under the curve (PAP‐AUC) remains the gold standard
method for detection of hVISA [10]. PAP‐AUC method is performed as follows:
The isolate is incubated in tryptone soya broth (TSB) for 24 h. An undiluted culture and
dilutions of 1/108 and 1/105 are spiral plated onto BHIA plates containing 0.5, 1, 2, 2.5, 4, and
8 μg of vancomycin per ml. After 48 h of incubation at 35°C, the colonies are counted. Log10
of the colony numbers (log10 CFU/ml) are plotted against the vancomycin concentrations. The
“area under the curve (AUC)” of the isolate is calculated. The VSSA strain ATCC 29213 is used
as negative control. Reference strains of hVISA (Mu3, ATCC 700698) and VISA (Mu50, ATCC
700699) are used as positive controls. A ratio is calculated by dividing the AUC of the test
strain by the AUC of reference hVISA strain (Mu3). The ratios of <0.90, 0.90–1.30, and >1.30
are interpreted as VSSA, hVISA, and VISA, respectively [28, 33]. Figure 8 shows an example
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of population analysis for S. aureus ATCC 29213 (VSSA), Mu3 (hVISA), Mu50 (VISA), a clinical
hVISA isolate and a clinical VSSA isolate [11].
Figure 8. Example of population analysis profile curves for S. aureus ATCC 29213 (VSSA), Mu3 (hVISA), Mu50 (VISA),
a clinical hVISA isolate and a clinical VSSA isolate. (Adapted from Ref. [11] which was published under an open‐access
licence agreement).
Unfortunately, PAP‐AUC method is time‐consuming, labor‐intensive and costly which limits
its use in routine clinical laboratories.
5. Epidemiology
While VRSA strains are limited to a handful of reported cases (14 total cases of VRSA in the
U.S.) and VISA strains remain rare; hVISA strains are more common [9, 12, 34]. The true
prevalence of hVISA is unknown, and estimates vary widely due to nonstandardized detection
methods or absence of routine hVISA screening, variation in interpretation, clinical setting,
geographical region, and differing patient populations [35]. Global hVISA rates among MRSA
isolates have been reported to range from 0 to 73.7% [36].
In many studies, only the isolates suspected of being hVISA by screening methods (screening
plates, Etest macromethod, Etest GRD) have been subjected to PAP‐AUC. Some hVISA isolates
may have been missed by screening methods in these studies. This may lead to an underesti‐
mation of the true prevalence [2, 27].
Although reported predominantly for MRSA; hVISA/VISA can be detected among methicil‐
lin‐susceptible S. aureus (MSSA) strains [2, 37]. However, routine testing of MSSA isolates for
the presence of hVISA/VISA for clinical purposes is not necessary and not recommended [10].
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High‐level resistance to vancomycin in S. aureus is very rare and all VRSA strains reported to
date have been MRSA [9].
The proportion of S. aureus isolates demonstrating heteroresistance increases with increasing
vancomycin MICs within the susceptible range, but heteroresistance has been reported in
strains with MICs as low as 0.5 μg/ml [21, 38].
The main risk factors for hVISA and VISA infection appear to be prior MRSA colonization or
infection and exposure to vancomycin. Most of hVISA/VISA infections occur in patients with
serious underlying diseases such as malignancy, renal failure and diabetes, or in patients who
have undergone major surgery [2, 12]. Nosocomial spread and rare outbreaks caused by VISA
or hVISA have also been reported [34].
6. Clinical significance of hVISA/VISA and VRSA
The clinical significance of hVISA/VISA is difficult to determine due to differences in defini‐
tions and laboratory detection as well as the lack of well‐controlled prospective studies [2, 21].
Commonly reported associations with hVISA/VISA infections include vancomycin treatment
failure and high‐inoculum infections such as bacteremia, endocarditis, deep abscesses,
osteomyelitis, and prosthetic device infections [2, 21, 35, 36]. Some authors consider that
hVISA/VISA could be responsible for treatment failure, whereas others have suggested that
it has arisen as a consequence of treatment failure and prolonged vancomycin exposures [39].
It is difficult to determine, especially if it is not clear when the VISA or hVISA isolate was
detected in the course of infection [21].
Interestingly, attenuated virulence of S. aureus with reduced susceptibility to vancomycin has
been reported in some animal infection models [40, 41]. Pooled data from a meta‐analysis
showed similar mortality rates for hVISA and VSSA infections [36]. However, two recent
studies have found a link between hVISA and higher mortality rate. Claeys et al. reported that
patients with hVISA pneumonia experienced significantly higher inpatient mortality than
those with VSSA pneumonia [42]. Hu et al. demonstrated that patients with hVISA bacteremia
had a significantly higher in‐hospital mortality than those with VSSA bacteremia [43].
The clinical significance of VRSA is unclear as only a few cases have been reported to date.
Persistent signs of infection and positive cultures for MRSA despite the administration of
glycopeptide therapy, or relapse of infection after glycopeptide therapy can suggest an
infection with hVISA or VISA [12]. Well‐designed, large‐scale prospective studies are needed
to evaluate the clinical significance of these strains.
7. Therapeutic options
7.1. Role of surgery
Many patients with infections due to hVISA/VISA have high‐inoculum infections (endocar‐
ditis, deep abscesses, osteomyelitis/septic arthritis and prosthetic device infections) [2, 12, 36].
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Surgery is a useful adjunct to antimicrobial therapy for these patients. Main types of surgery
include the drainage of abscesses or infected joints and removal of the infected prostheses [12].
7.2. Antimicrobial therapy
The emergence of hVISA/VISA clinical isolates has prompted the search for new antibiotics.
While there are no guidelines regarding alternative antimicrobial therapy, there are a number
of antimicrobial agents that have potential to be used in treatment of hVISA/VISA infections.
7.2.1. Daptomycin
Daptomycin is a lipopeptide antibiotic with activity against Gram‐positive bacteria. In a study
conducted by Wootton et al., despite slightly raised MICs seen for strains with reduced
susceptibility to vancomycin; daptomycin showed greater bactericidal activity than vanco‐
mycin for hVISA and VISA [44]. This indicates that, while there is a potential for cross‐
resistance between daptomycin and vancomycin, susceptibility to daptomycin is minimally
affected by the presence of hVISA or VISA [10]. In several studies, daptomycin has been shown
to have a good antimicrobial activity against the majority of hVISA isolates [27, 44, 45]. The
highest rate of daptomycin nonsusceptibility was reported in a study evaluating 47 isolates of
hVISA/VISA. In this study, the percentage of daptomycin nonsusceptible isolates was 15% for
hVISA and 38% for VISA [35, 46]. Additionally, daptomycin has been shown to have in vitro
activity against VRSA isolates. In a study conducted by Sievert et al., one daptomycin nonsus‐
ceptible isolate was observed among 7 VRSA [47].
7.2.2. Linezolid
Linezolid is a synthetic antibacterial agent of the oxazolidinone class. Although resistance to
linezolid has been reported in S. aureus isolates, rates of resistance remain very low. Linezolid
was found to be useful for the treatment of hVISA/VISA infections [2, 48]. Also, data from a
study demonstrated potent in vitro activity for linezolid against VRSA strains [47]. However,
treatment with linezolid may be limited by toxicity. High rates of adverse reactions have been
found for complex patients (seriously ill patients with multiple comorbidities) who received
prolonged linezolid therapy [49]. Therefore, prolonged therapy should be used with caution
in this patient group.
7.2.3. Tigecycline
Tigecycline is a glycylcycline antibiotic for intravenous infusion. In a study conducted by Sun
et al., 26 hVISA isolates and 1 VISA isolate were tested for tigecycline susceptibility. All isolates
were found to be susceptible to tigecycline [50]. In another study, in vitro activity of tigecycline
was evaluated against 33 VISA and 13 VRSA isolates. Tigecycline susceptibility rates were 97
and 92% for VISA and VRSA, respectively [51]. In vitro data have shown that tigecycline is
active against hVISA/VISA as well as VRSA. Clinical studies are needed to determine the role
of tigecycline in infections caused by S. aureus with reduced susceptibility to vancomycin.
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7.2.4. New cephalosporins
New cephalosporins like ceftaroline and ceftobiprole have been shown to be active against
hVISA and VISA in vitro and in animal studies. In rabbit models of endocarditis, these agents
were superior to vancomycin against hVISA and VISA [2]. While results of in vitro and in vivo
testing of these cephalosporins have been positive against hVISA/VISA, their clinical utility
for infections caused by hVISA or VISA remains unknown [10].
7.2.5. Other antimicrobial agents
Other potentially active antimicrobials include lipoglycopeptides (dalbavancin, oritavancin,
telavancin), quinupristin‐dalfopristin, rifampin and fusidic acid. However, resistance devel‐
ops rapidly with monotherapy with rifampin or fusidic acid. Therefore, these agents should
be used in combination with another antistaphylococcal agent. The combination of rifampin
and fusidic acid is an effective option [2]. Studies also suggest the potential for synergistic
activity between vancomycin and various antimicrobials including beta‐lactams and genta‐
micin against S. aureus with reduced vancomycin susceptibility [10].
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